Growth hormone secretagogue: difference between revisions
Diff·revision 10 → 11·23:01, 12 Apr 2025
Difference between revision 10 and revision 11 of Growth hormone secretagogue. 1 line changed; the page grew by 44 bytes.
| Revision 10 — 03:59, 25 Mar 2025 TesamorelinTeg (talk) move the vendor-availability paragraph out; that is not article material 3,576 bytes +143 | Revision 11 — 23:01, 12 Apr 2025 CiteBot (talk) bot: flag bare reference 3,620 bytes +44 | ||
|---|---|---|---|
| 7 | | Approved example = Tesamorelin, for a specific indication | 7 | | Approved example = Tesamorelin, for a specific indication |
| 8 | }} | 8 | }} |
| + | 9 | {{medical|talk=Unapproved-compound notice}} | |
| 9 | 10 | ||
| 10 | '''Growth hormone secretagogues''' are compounds that stimulate release of endogenous growth hormone, in contrast to administration of growth hormone itself. Two receptor families are involved: the receptor for growth hormone-releasing hormone, and the ghrelin receptor GHS-R1a.{{r|sigalos2018}} | 11 | '''Growth hormone secretagogues''' are compounds that stimulate release of endogenous growth hormone, in contrast to administration of growth hormone itself. Two receptor families are involved: the receptor for growth hormone-releasing hormone, and the ghrelin receptor GHS-R1a.{{r|sigalos2018}} |